Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes

Fredirick Mashili1, Alexander V Chibalin, Anna Krook

  • 1Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Diabetes
|October 9, 2012
PubMed

Insights

Excessive STAT3 signaling contributes to skeletal muscle insulin resistance in type 2 diabetes (T2D). Silencing STAT3 prevents lipid-induced insulin resistance in muscle cells, highlighting its role in T2D pathogenesis.

Area of Science:

  • Metabolic diseases
  • Molecular biology
  • Cellular signaling

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is implicated in insulin resistance.
  • The specific role of STAT3 in skeletal muscle insulin resistance and type 2 diabetes (T2D) requires further elucidation.

Purpose of the Study:

  • To investigate the hypothesis that STAT3 signaling contributes to skeletal muscle insulin resistance in T2D.
  • To determine the role of STAT3 in lipid-induced insulin resistance in skeletal muscle.

Main Methods:

  • Analysis of STAT3 signaling molecules in skeletal muscle biopsies from normal glucose tolerant (NGT) and T2D patients.
  • In vitro studies using L6 myotubes exposed to palmitate and treated with STAT3 siRNA.

Main Results:

  • Increased phosphorylated STAT3, JAK2, and SOCS3 in skeletal muscle of T2D patients.
  • STAT3 phosphorylation correlated with insulin sensitivity in NGT individuals.
  • Palmitate-induced insulin resistance and SOCS3 increase in myotubes were prevented by STAT3 silencing.

Conclusions:

  • STAT3 is constitutively phosphorylated in skeletal muscle of T2D patients.
  • STAT3 gene silencing mitigates lipid-induced insulin resistance in cultured myotubes.
  • Aberrant STAT3 signaling is implicated in the development of skeletal muscle insulin resistance in T2D.

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...